European journal of radiology
-
Randomized Controlled Trial Multicenter Study Comparative Study
Efficacy and safety of gadodiamide (Gd-DTPA-BMA) in renal 3D-magnetic resonance angiography (MRA): a phase II study.
To determine the most efficacious dose of gadodiamide for three-dimensional (3D) contrast-enhanced (CE) magnetic resonance angiography (MRA) of the renal arteries on a patient level based on the sensitivity in detecting the main hemodynamically relevant (> or =50% or occlusion) renal artery stenosis (RAS) using intra-arterial digital subtraction angiography (IA DSA) as the gold standard. ⋯ A significant dose trend between the four doses examined was observed. The lowest dose (0.01mmol/kg) differed significantly from those of the other three doses. Based on the analysis of the primary and secondary endpoints, 0.1mmol/kg gadodiamide appears to be the most suitable dose in diagnosing hemodynamically relevant RAS. The present study also demonstrated gadodiamide to be safe and well tolerated.
-
To evaluate the structural and metabolic characteristics of atelectasis in FDG-PET/CT. ⋯ There is a positive relationship between the density of collapsed lung and the intensity of FDG uptake. FDG uptake in atelectasis is higher than in normal lung, and generally lower than in tumor tissue.